Emerging Applications Powering Therapeutic Discovery With David Curtin

At ASMS 2025, the Technology Networks team caught up with David Curtin, Vice President and GM, Biologics Business with Waters. He shared how Waters is expanding its portfolio to better support both large and small molecule manufacturers. David also highlighted how new application developments are helping advance a wide range of therapeutic research efforts.

Watch the full episode to learn more about Waters’ latest acquisitions and how they're shaping the future of biopharma.